S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift

NeuBase Therapeutics (NBSE) Short Interest Ratio & Short Volume

$0.72
-0.02 (-2.70%)
(As of 02/21/2024 ET)

NeuBase Therapeutics Short Interest Data

Current Short Volume
12,600 shares
Previous Short Volume
11,000 shares
Change Vs. Previous Month
+14.55%
Dollar Volume Sold Short
$8,983.80
Short Interest Ratio / Days to Cover
0.0
Last Record Date
January 31, 2024
Outstanding Shares
3,730,000 shares
Float Size
3,030,000 shares
Short Percent of Float
0.42%
Today's Trading Volume
57,096 shares
Average Trading Volume
44,961 shares
Today's Volume Vs. Average
127%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling NeuBase Therapeutics ?

Sign up to receive the latest short interest report for NeuBase Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

NBSE Short Interest Over Time

NBSE Days to Cover Over Time

NBSE Percentage of Float Shorted Over Time


NeuBase Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/31/202412,600 shares $8,983.80 +14.6%0.4%0 $0.71
1/15/202411,000 shares $7,291.90 -82.6%0.4%0 $0.66
12/31/202363,300 shares $46,848.33 +245.9%2.1%0.2 $0.74
12/15/202318,300 shares $12,810.00 +105.6%0.6%0.1 $0.70
11/30/20238,900 shares $8,778.96 -27.6%0.3%0 $0.99
11/15/202312,300 shares $8,007.30 +38.2%0.5%0 $0.65
10/31/20238,900 shares $5,651.50 -53.9%0.6%0 $0.64
10/15/202319,300 shares $14,457.63 -15.4%1.2%0 $0.75
9/30/202322,800 shares $19,831.44 -89.9%1.4%0 $0.87
9/15/2023225,600 shares $293,280.00 +30.8%14.0%0.1 $1.30
8/31/2023172,500 shares $167,325.00 +130.3%19.3%0.1 $0.97
8/15/202374,900 shares $51,531.20 +82.2%3.8%0.4 $0.69
7/31/202341,100 shares $57,129.00 -61.4%2.4%0.3 $1.39
7/15/2023106,600 shares $187,616.00 +49.1%7.5%1.4 $1.76
6/30/202371,500 shares $132,275.00 +108.5%5.0%1 $1.85
6/15/202334,300 shares $1.89 million -93.8%2.4%0.5 $55.20
5/31/2023554,800 shares $98,809.88 -1.7%2.0%1.2 $0.18
5/15/2023564,400 shares $108,929.20 +0.7%2.0%1.3 $0.19
4/30/2023560,400 shares $75,654.00 +64.4%2.0%1.1 $0.14
4/15/2023340,900 shares $57,271.20 +35.5%1.2%0.7 $0.17
3/31/2023251,600 shares $46,546.00 -8.1%0.9%0.8 $0.19
3/15/2023273,800 shares $51,282.74 -15.1%1.0%0.8 $0.19
2/28/2023322,500 shares $74,175.00 -46.3%1.2%0.9 $0.23
2/15/2023600,100 shares $169,708.28 +127.1%2.2%1.8 $0.28
1/31/2023264,300 shares $60,181.11 -13.2%0.9%1 $0.23
1/15/2023304,400 shares $78,961.36 -24.7%1.0%1.2 $0.26
12/30/2022404,400 shares $76,916.88 +27.1%1.4%1.8 $0.19
12/15/2022318,200 shares $63,130.88 +12.0%1.1%1.7 $0.20
11/30/2022284,200 shares $68,122.74 -5.1%1.0%1.8 $0.24
11/15/2022299,500 shares $86,855.00 -24.1%1.0%1.9 $0.29
10/31/2022394,500 shares $113,221.50 +11.8%1.4%3.2 $0.29
10/15/2022353,000 shares $95,592.40 +10.4%1.2%3.4 $0.27
9/30/2022319,900 shares $126,360.50 -3.6%1.1%4.3 $0.40
9/15/2022331,700 shares $181,771.60 -3.8%1.1%5.1 $0.55
8/31/2022344,800 shares $208,810.88 -7.0%1.2%5.5 $0.61
8/15/2022370,900 shares $422,826.00 -2.2%1.3%6.4 $1.14
7/31/2022379,400 shares $405,958.00 -0.3%1.3%7.6 $1.07
7/15/2022380,700 shares $380,700.00 -4.5%1.3%6.9 $1.00
6/30/2022398,500 shares $418,425.00 -10.2%1.3%6.7 $1.05
6/15/2022443,900 shares $412,827.00 +11.5%16.5%6.8 $0.93













NBSE Short Interest - Frequently Asked Questions

What is NeuBase Therapeutics' current short interest?

Short interest is the volume of NeuBase Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 31st, investors have sold 12,600 shares of NBSE short. 0.42% of NeuBase Therapeutics' shares are currently sold short. Learn More on NeuBase Therapeutics' current short interest.

Which institutional investors are shorting NeuBase Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of NeuBase Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for NeuBase Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.42% of NeuBase Therapeutics' floating shares are currently sold short.

Is NeuBase Therapeutics' short interest increasing or decreasing?

NeuBase Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totaling 12,600 shares, an increase of 14.5% from the previous total of 11,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is NeuBase Therapeutics' float size?

NeuBase Therapeutics currently has issued a total of 3,730,000 shares. Some of NeuBase Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NeuBase Therapeutics currently has a public float of 3,030,000 shares.

How does NeuBase Therapeutics' short interest compare to its competitors?

0.42% of NeuBase Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to NeuBase Therapeutics: Aptevo Therapeutics Inc. (0.09%), Notable Labs, Ltd. (0.23%), Clearmind Medicine Inc. (5.40%), Qualigen Therapeutics, Inc. (0.64%), Aravive, Inc. (1.81%), Altamira Therapeutics Ltd. (4.43%), Ensysce Biosciences, Inc. (23.32%), Sonoma Pharmaceuticals, Inc. (0.81%), Cyclacel Pharmaceuticals, Inc. (9.29%), Processa Pharmaceuticals, Inc. (12.47%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.48 billion), General Motors ($3.85 billion), Charter Communications, Inc. ($3.38 billion), Occidental Petroleum Co. ($3.00 billion), Super Micro Computer, Inc. ($2.66 billion), Tractor Supply ($2.37 billion), Coinbase Global, Inc. ($2.25 billion), Moderna, Inc. ($2.11 billion), Royal Caribbean Cruises Ltd. ($2.06 billion), and Floor & Decor Holdings, Inc. ($1.67 billion). View all of the most shorted stocks.

What does it mean to sell short NeuBase Therapeutics stock?

Short selling NBSE is an investing strategy that aims to generate trading profit from NeuBase Therapeutics as its price is falling. NBSE shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against NeuBase Therapeutics?

A short squeeze for NeuBase Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NBSE, which in turn drives the price of the stock up even further.

How often is NeuBase Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NBSE, twice per month. The most recent reporting period available is January, 31 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:NBSE) was last updated on 2/22/2024 by MarketBeat.com Staff